Icon expands UK and US labs

- Last updated on GMT

Icon adds to US and UK biomarkers business
Icon has added bioanalytical testing capacity at sites in the US and UK citing demand for biomarkers as the key driver for the investment.

The Ireland-based contract research organisation (CRO) added space at its facilities in Whitesboro, New York, and Manchester, UK, which will house dedicated immunoassay laboratories.

Brian O’Dwyer, senior VP of Global Bioanalytical Services at Icon said: “We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors​.

In particular, the expansion of our dedicated biomarker testing laboratories allows us to support biomarker development programs across multiple testing platforms globally​.”

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers